Last updated: September 8, 2026
Mitotane is a mature orphan oncology drug used primarily for adrenocortical carcinoma and control of adrenal hormone production. Its market is small, medically specialized, and protected more by clinical scarcity, monitoring requirements, supply-chain complexity, and limited competition than by meaningful patent exclusivity. Public financial disclosures do not identify mitotane revenue as a standalone line item, so the product’s financial trajectory must be assessed through patient volume, pricing, regulatory status, ownership, and competitive access.
What is mitotane used for, and how large is the market?
Mitotane is an adrenolytic agent approved for inoperable adrenocortical carcinoma, a rare malignancy arising in the adrenal cortex. It is also used in specialist practice to control cortisol or androgen excess, including in patients with advanced adrenal tumors or selected endocrine disorders. Its pharmacology requires prolonged treatment and therapeutic drug monitoring.
The addressable patient population is small. Published estimates generally place adrenocortical carcinoma incidence at approximately 0.7 to 2 cases per million people annually, with geographic variation. The United States therefore has an estimated annual incidence in the low hundreds, while the global incident population is several thousand patients per year at most. Not every patient receives mitotane, and many patients discontinue treatment because of toxicity, disease progression, or inability to reach therapeutic concentrations.
| Market characteristic |
Mitotane implication |
| Primary disease |
Adrenocortical carcinoma |
| FDA status |
Approved prescription drug |
| Dosage form |
Oral tablets, historically 500 mg |
| Treatment duration |
Often prolonged, including maintenance use |
| Patient monitoring |
Plasma mitotane levels, adrenal function, electrolytes, liver tests |
| Typical specialist base |
Endocrinology, oncology, tertiary referral centers |
| Market size |
Rare-disease market with low absolute patient volume |
| Main commercial constraint |
Limited patient pool rather than broad demand |
The narrow patient population supports high per-patient revenue potential, but it also limits total sales. Product availability is strategically important because alternatives are limited, yet the market cannot support the commercial scale of a conventional oncology product.
What is the FDA regulatory status of mitotane?
Mitotane is an FDA-approved drug marketed under the brand name Lysodren. The product received approval decades ago, and its regulatory position is distinct from that of newer molecularly targeted adrenal cancer therapies.
The main FDA-approved use is for patients with inoperable adrenocortical carcinoma. The prescribing information identifies mitotane as a drug with substantial variability in absorption and a long terminal elimination period. Treatment generally begins at a lower dose and is increased according to tolerance, clinical response, and plasma concentration.
Mitotane is not a biologic. Biosimilar competition does not apply. Competition arises through generic or multisource oral products, regulatory reapproval, authorized-generic arrangements, and alternative endocrine or oncology treatments.
What are the principal clinical barriers to use?
Mitotane has a narrow therapeutic window and significant toxicity. Common management issues include:
- Gastrointestinal toxicity, including nausea, vomiting, diarrhea, and anorexia.
- Neurologic effects, such as dizziness, ataxia, sedation, and cognitive impairment.
- Adrenal insufficiency requiring glucocorticoid and sometimes mineralocorticoid replacement.
- Hepatic monitoring requirements.
- Drug interactions caused by enzyme induction.
- Delayed attainment of therapeutic concentrations.
- Long persistence in adipose tissue and slow clearance after discontinuation.
These factors reduce the number of patients who can remain on treatment and raise the clinical burden associated with switching products. They also create practical barriers for new entrants, even when the active ingredient itself is old.
When does mitotane lose exclusivity?
Mitotane’s original active-ingredient and basic product protection expired long ago. It is not protected today by the type of foundational composition-of-matter patent that supports exclusivity for a modern small-molecule launch.
| Exclusivity element |
Current commercial relevance |
| Original compound patent |
Expired |
| Original FDA approval exclusivity |
Expired |
| Orphan-drug exclusivity |
Historical or expired for the original product |
| Basic tablet formulation protection |
Expired or no longer commercially decisive |
| Biosimilar exclusivity |
Not applicable |
| Current patent moat |
Limited |
| Practical moat |
Specialist use, monitoring, supply reliability, and limited competition |
The exact commercial position depends on jurisdiction and the status of individual manufacturers. Patent expiry does not automatically produce broad generic availability in a market with a small patient population, difficult procurement, and limited manufacturing economics.
What patents protect mitotane today?
Mitotane’s principal commercial asset is the active pharmaceutical ingredient itself, not a current patent estate. Publicly available product information does not indicate a material active patent portfolio covering the basic mitotane molecule.
Are there formulation patents for mitotane?
Historical or jurisdiction-specific formulation claims may exist, but they do not appear to create a broad, durable barrier comparable to an extended-release, injectable, or complex delivery system. The standard product is an oral tablet containing an old small molecule.
A potential entrant would still need to address:
- Pharmaceutical equivalence.
- Bioequivalence or an appropriate regulatory bridge.
- Dissolution and content uniformity.
- Stability and packaging.
- Manufacturing controls for a low-volume oncology product.
- Reliable supply of active pharmaceutical ingredient.
- Post-market pharmacovigilance.
These issues can delay or discourage entry without creating patent-based exclusivity.
Are method-of-use patents important?
Method-of-use patent protection is not the principal barrier for mitotane. Its main approved use has been established for decades. A later patent covering a narrow dosing approach, therapeutic drug-monitoring strategy, combination regimen, or endocrine indication could have limited relevance, but such claims would not ordinarily prevent generic use for the core approved indication unless enforceable and listed in the relevant jurisdiction.
What is the Orange Book status of mitotane?
The FDA Orange Book is the primary U.S. reference for approved drug products, therapeutic equivalence evaluations, and listed patents. Mitotane’s Orange Book position should be assessed by reviewing the current entry for the relevant NDA, product sponsor, and dosage form.
The commercial interpretation is straightforward:
- The underlying active ingredient is old.
- Any original product exclusivity has expired.
- The central question is whether current listed patents exist for the marketed product.
- A lack of meaningful listed patents would leave regulatory approval, manufacturing, and commercial execution as the principal entry barriers.
Because sponsor and product records can change after transfers, discontinuations, or reintroductions, the current Orange Book listing should control any litigation or launch decision. Historical ownership should not be treated as proof of current patent rights.
Which companies manufacture or market mitotane?
The commercial history of mitotane has involved changes in brand ownership, distribution, and regional marketing rights. Lysodren has been associated with specialist pharmaceutical companies and rare-disease commercial platforms rather than a large diversified primary-care business.
The market may include:
- The branded Lysodren product.
- Regional distributors or licensees.
- Generic manufacturers in jurisdictions where generic mitotane is approved.
- Hospital and specialty-pharmacy channels.
- Compounding or extemporaneous supply in markets experiencing shortages, subject to local law.
Ownership and distribution arrangements have changed over time. The product has been associated with HRA Pharma and rare-disease commercial operations, while corporate transactions have altered portfolio ownership and regional responsibility. A transaction involving a parent company does not necessarily transfer every mitotane right in every country.
What manufacturing barriers affect mitotane?
Manufacturing is a more important barrier than molecular innovation.
Mitotane requires a dependable source of active ingredient and a production process capable of maintaining tablet quality at relatively low volume. Commercial risks include:
- Limited API suppliers.
- Low batch economics.
- Inventory requirements caused by long treatment duration.
- Small numbers of qualified manufacturing sites.
- Specialty-pharmacy distribution.
- Regulatory scrutiny after supply interruptions.
- Patient sensitivity to changes in exposure.
The market can therefore remain concentrated even without active patents. A generic manufacturer must expect modest volume, regulatory expense, and a need to maintain supply continuity for a medically fragile population.
How many companies are challenging mitotane exclusivity?
Mitotane does not present the typical modern branded-drug challenge pattern involving multiple Paragraph IV certifications against a recently issued patent estate. Its principal patent barriers are old or limited, and the market is too small to attract the number of generic challengers seen in high-revenue chronic therapies.
Publicly visible competition is better evaluated through product availability than through patent litigation. A company can enter with little litigation risk but still decline to launch because expected revenue does not justify development and manufacturing costs.
What is the Paragraph IV risk for mitotane?
Paragraph IV risk appears low relative to products with active Orange Book patents. A generic applicant could still submit a Paragraph IV certification if a relevant listed patent exists, but the economic incentive to litigate would depend on the remaining market, the patent’s scope, and the sponsor’s ability to defend it.
For an old oral drug, the more likely entry pathway is an abbreviated regulatory filing supported by relevant bioequivalence data and certification that no blocking patent remains, rather than a high-value patent challenge designed to secure 180-day exclusivity.
What patent litigation affects mitotane?
Mitotane has not generated a widely recognized, high-value patent litigation campaign comparable to blockbuster oncology drugs. The principal legal risks are more likely to involve:
- Product liability.
- Supply contracts.
- Distribution rights.
- Trademark ownership.
- Regulatory status of discontinued or reintroduced products.
- Generic approval and therapeutic-equivalence disputes.
- Shortage-related procurement conflicts.
The absence of major patent litigation is consistent with the age of the active ingredient and the limited value of its patent estate.
How does mitotane compare with competing adrenal cancer treatments?
Mitotane remains a distinctive treatment because it directly suppresses or destroys adrenal cortical tissue. However, its clinical position is affected by alternative systemic therapies and combination regimens.
| Treatment category |
Role relative to mitotane |
Commercial effect |
| Mitotane monotherapy |
Adjuvant or systemic treatment in selected adrenal cancer patients |
Supports durable specialist demand |
| Cytotoxic chemotherapy |
Used in advanced disease and combinations |
Limits mitotane monotherapy share |
| Etoposide, doxorubicin, cisplatin regimens |
Established systemic options |
Compete in advanced disease |
| Steroidogenesis inhibitors |
Control hormone excess rather than directly replacing mitotane’s tumor effect |
Complementary or alternative endocrine use |
| Immunotherapy |
Investigational or selected off-label use depending on jurisdiction |
Creates long-term substitution risk |
| Clinical trials |
Access to novel targeted or immune therapies |
Can reduce treatment volume at specialist centers |
Mitotane is more exposed to clinical substitution than to patent substitution. New therapies do not need to replicate its mechanism to reduce use; they only need to improve efficacy, tolerability, convenience, or disease control in defined patient groups.
What is mitotane’s financial trajectory?
Mitotane’s revenue profile is likely stable to modestly declining in mature markets, with periodic increases from price, product transfers, geographic expansion, or supply normalization rather than from substantial patient growth.
Public company reports generally do not disclose standalone mitotane revenue. The product is typically grouped within a rare-disease or specialty-pharmaceutical portfolio. As a result, precise revenue, gross margin, and EBITDA figures cannot be derived from public filings without company-specific product reporting.
Financial drivers
| Driver |
Directional impact |
| Rare-disease pricing |
Positive per-patient revenue |
| Small incidence base |
Limits total sales |
| Long treatment duration |
Supports recurring revenue |
| Treatment discontinuation |
Reduces persistence |
| Therapeutic monitoring |
Limits broad prescribing |
| Limited alternatives |
Supports demand resilience |
| Generic entry |
Creates price and share pressure |
| Supply interruptions |
Can reduce revenue and damage trust |
| Corporate portfolio ownership |
Can change reported economics |
| New adrenal cancer therapies |
Long-term volume risk |
Mitotane is financially attractive as a niche asset when sold through an established rare-disease platform. It is less attractive as a standalone acquisition because the product has limited growth, no obvious core-patent renewal path, and operational dependence on specialist distribution.
What generic launch scenarios exist for mitotane?
Scenario 1: No material generic launch
The incumbent retains most demand because the market is too small for several generic manufacturers. Revenue remains supported by price and specialist familiarity. This is the most favorable scenario for the branded product.
Scenario 2: Single-generic entry
One generic manufacturer enters after regulatory approval. The entrant captures price-sensitive accounts and selected institutional business, while the branded product retains patients whose physicians prioritize continuity of supply.
Scenario 3: Multiple generic entrants
Price declines become more pronounced, especially in tender-driven markets. The incumbent may respond through contracting, authorized-generic supply, or regional distribution changes. This scenario requires sufficient market value to support multiple manufacturers.
Scenario 4: Supply-driven disruption
A manufacturing interruption creates temporary shortages. Patients may shift to alternative suppliers, imports, or hospital procurement channels. Revenue can become volatile, and regulatory authorities may impose additional supply obligations.
Scenario 5: Clinical substitution
A new systemic therapy or combination regimen reduces mitotane use in advanced disease. This would affect volume more than a generic launch because it could reduce the total number of patients receiving the drug.
What geographic markets matter most?
The United States is commercially important because of specialty pricing and the presence of a rare-disease reimbursement infrastructure. Europe is fragmented across national reimbursement systems, hospital procurement, and marketing-authorisation arrangements. Countries with established endocrine oncology centers may have relatively high use despite small populations.
Geographic risks include:
- Different approval holders by country.
- Importation controls.
- National price negotiations.
- Hospital-only distribution.
- Reimbursement restrictions.
- Local shortages.
- Different rules for compounded or unlicensed supply.
A global mitotane valuation should therefore avoid applying a single U.S. price or patient estimate to all territories.
How strong is the mitotane patent estate?
The patent estate is weak by modern pharmaceutical standards. The product’s economic durability rests on market structure rather than exclusivity.
| Strength dimension |
Assessment |
| Composition-of-matter protection |
Minimal or expired |
| Formulation protection |
Limited |
| Method-of-use protection |
Limited for the core indication |
| Regulatory exclusivity |
Expired or historical |
| Manufacturing complexity |
Moderate |
| Supply-chain barrier |
Moderate to high |
| Clinical switching barrier |
Moderate to high |
| Generic litigation risk |
Low to moderate |
| Long-term substitution risk |
Moderate |
The asset can generate recurring cash flow, but its value is defensive rather than growth-oriented. A buyer would be underwriting brand continuity, pricing discipline, supply reliability, and specialist relationships rather than a patent-backed monopoly.
What licensing and acquisition activity affects mitotane?
Mitotane rights have historically moved through specialty and rare-disease companies. Such transactions generally reflect portfolio consolidation, regional commercialization, or transfer of mature products rather than discovery-stage licensing.
The key diligence points are:
- Territory-specific marketing rights.
- Whether the holder owns the NDA or only commercial rights.
- Manufacturing and supply obligations.
- Rights to trademarks and regulatory files.
- Responsibility for pharmacovigilance.
- Existing distributor and specialty-pharmacy contracts.
- Change-of-control provisions.
- Obligations arising from shortages or product discontinuation.
A transaction price based on headline rare-disease revenue could overstate the asset’s strategic value if the product lacks patent protection or faces a low-volume generic launch.
Key Takeaways
- Mitotane is a mature oral orphan oncology drug used mainly for adrenocortical carcinoma.
- Its market is small, specialist-driven, and relatively resilient because therapeutic alternatives remain limited.
- Original compound and product exclusivity have expired.
- The current patent moat is weak; manufacturing, supply, monitoring, and clinical familiarity are more important barriers.
- Biosimilar risk does not apply because mitotane is a small-molecule drug.
- Paragraph IV and patent-litigation risk appear lower than for newer branded oncology products.
- Standalone mitotane revenue is not generally disclosed in public company filings.
- Financial performance is likely driven by price, persistence, supply continuity, and regional rights rather than patient growth.
- Generic entry could reduce price and institutional share without immediately eliminating the branded product.
- New adrenal cancer therapies represent the main long-term volume risk.
FAQs
Is mitotane still under patent?
The original mitotane molecule and basic product protection are long expired. Any current protection would need to arise from a specific formulation, method of use, or jurisdiction-specific right rather than the active ingredient itself.
Is Lysodren a biologic or a small-molecule drug?
Lysodren is a conventional small-molecule oral drug. It is not subject to biosimilar approval pathways.
Why can mitotane remain expensive after patent expiry?
The patient population is very small, treatment requires specialist monitoring, supply interruptions can be consequential, and few manufacturers may find the market economically attractive.
Can a generic manufacturer substitute automatically for Lysodren?
Automatic substitution depends on regulatory approval, therapeutic-equivalence status, local pharmacy law, reimbursement rules, and physician or hospital policy. It is not determined by patent expiry alone.
What would most damage mitotane revenue?
The largest risks are a reliable low-cost generic launch, sustained supply disruption, or a new adrenal cancer therapy that replaces mitotane in systemic treatment or hormone-control protocols.
References
-
U.S. Food and Drug Administration. (2024). Lysodren (mitotane) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
National Cancer Institute. (2024). Adrenocortical carcinoma treatment. National Cancer Institute.
-
Fassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., De Krijger, R., Haak, H. R., Mihailovic, D., Assie, G., Terzolo, M., & the European Society of Endocrinology. (2018). European Society of Endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults. European Journal of Endocrinology, 179(4), G1-G46.
-
Stigliano, A., Chiodini, I., Carlsen, S., Bugalho, M. J., Kazakou, P., Roldan, D., López, M. R., Loli, P., Giordano, R., Arnaldi, G., & others. (2017). Management of adrenocortical carcinoma: A consensus statement. European Journal of Endocrinology, 176(2), P1-P14.
